Shandong Weigao Group Medical Polymer Co. Ltd. Class H

As of December 31, 2025, Shandong Weigao Group Medical Polymer Co., Ltd. carries a market capitalization of 3.15B, placing it among publicly traded companies globally. Its enterprise value stands at 2.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shandong Weigao Group Medical Polymer Co., Ltd.'s next confirmed earnings release is scheduled for March 30, 2027.

As of December 31, 2025, Shandong Weigao Group Medical Polymer Co., Ltd. has 4.48B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Shandong Weigao Group Medical Polymer Co., Ltd. maintains a current ratio of 3.78, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on September 25, 2026, Shandong Weigao Group Medical Polymer Co., Ltd.'s stock has declined approximately 45.09% over the past 52 weeks. The 50-day moving average sits at 0.99, while the 200-day moving average is 1.11.

As of December 31, 2025, Shandong Weigao Group Medical Polymer Co., Ltd. holds 1.35B in cash and equivalents against 729.83M in total debt, resulting in a net debt position of -540.63M. Total book value stands at 3.45B, with working capital of 2.17B providing operational flexibility.

Shandong Weigao Group Medical Polymer Co., Ltd.'s most recent stock split took place on May 4, 2011 with a 1:2 split ratio.